US/UK/Canada

Share

Contacts

  • Sarah van Hellenberg Hubar-Fisher

    CEO


    Yrittäjänkulma 5, FI-33710 Tampere, FINLAND
    +31 6 1544 8736
    https://bioretec.com/
  • Anne-Mari Matikainen

    Interim CFO


    Yrittäjänkulma 5, FI-33710 Tampere, Finland
    +358 50 322 1069
    https://bioretec.com/

    • Links

    Quotes

    It is an honor to announce this SAB and integrate these merited leaders of the orthopedic industry with our new RemeOs™ Screw products and material technology development. We are thrilled to have decades of the expertise and impactful accomplishments of SAB members behind us. Their combined resume includes significant professional and academic contributions and influential positions in the global orthopedic community. We are looking forward to this cooperation with our SAB and interesting future activities.
    Timo Lehtonen, CEO of Bioretec
    Pick a time period -
    Tags ( Active)

    Bioretec appoints Conan Cavanagh as Head of Research & Development and member of the Management Team

    Bioretec Ltd | Press Release | 17 June 2026 at 16:00 EEST   Bioretec Ltd, a pioneer in absorbable orthopedic implants, has appointed Conan Cavanagh as Head of Research & Development and as a member of the management team as of 1 September 2026. Cavanagh will report directly to CEO Sarah van Hellenberg Hubar-Fisher. Conan Cavanagh has over 25 years of experience in the development of medical devices, biomaterials, and product commercialization. He currently serves as Chief Operating Officer and Head of Research & Development at HidraMed Solutions. Previously, among other positions,

    Bioretec concludes change negotiations

    Bioretec Ltd, Press Release, 17 June 2026 at 9:00 EEST On 1 June 2026, Bioretec announced the initiation of change negotiations in accordance with the Finnish Act on Co-operation within Undertakings, focusing on the company’s production function in Finland. The aim of the negotiations was to streamline operations and consequently to improve the company’s competitiveness and profitability. The negotiations began on 8 June 2026 and were concluded today. At the start of the negotiations, the company estimated that the plans may impact the terms of employment of up to four individuals

    Bioretec Ltd – Manager’s transactions – van Hellenberg Hubar-Fisher

    Bioretec Ltd Company release 4 June 2026 at 14:25 p.m. EEST   Bioretec Ltd - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Sarah van Hellenberg Hubar-Fisher Position: Chief Executive Officer  Issuer: Bioretec Oy LEI: 7437008736AG7HY51K13 Notification type: INITIAL NOTIFICATION Reference number: 159307/6/8 ____________________________________________ Transaction date: 2026-06-02 Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME) Instrument type: SHARE ISIN: FI4000480454

    Bioretec Ltd – Manager’s transactions – Jordy Winters

    Bioretec Oy Company release 2 June 2026 at 13:25 p.m. EEST   Bioretec Oy - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Jordy Winters Position: Other senior manager  Issuer: Bioretec Oy LEI: 7437008736AG7HY51K13 Notification type: INITIAL NOTIFICATION Reference number: 158959/6/4 ____________________________________________ Transaction date: 2026-05-29 Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME) Instrument type: SHARE ISIN: FI4000480454 Nature of transaction:

    The Board of Directors of Bioretec Ltd resolved on a new stock option plan

    Bioretec Ltd Company Announcement     1 June 2026 at 19:05 p.m. EEST   THE BOARD OF DIRECTORS OF BIORETEC LTD RESOLVED ON A NEW STOCK OPTION PLAN The Board of Directors of Bioretec Ltd has resolved to establish a new stock option plan for key personnel and selected consultants of the Group. There is a weighty financial reason for the Company to issue stock options, as they are intended to form part of the incentive and commitment program for the Group's key personnel and consultants. The stock options are intended to encourage the participants to work on a long-term basis to

    Inside information: Bioretec initiates new change negotiations in production to enhance operational efficiency

    Inside information: Bioretec initiates new change negotiations in production to enhance operational efficiency Bioretec Ltd — Inside information — 1 June 2026 at 19:00 EEST   Bioretec Ltd initiates change negotiations in accordance with the Finnish Act on Co-operation within Undertakings. The aim of the negotiations is to streamline operations and consequently to improve the company’s competitiveness and profitability. The negotiations will focus on Bioretec’s production function in Finland. The change negotiations will commence on 8 June 2026 and are estimated to last for

    Bioretec Ltd - Managers' transactions - Paavola

    Bioretec Ltd Company Release 18 May 2026 at 1:45 p.m. EEST Bioretec Oy - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Tuukka Paavola Position: Chief Financial Officer  Issuer: Bioretec Oy LEI: 7437008736AG7HY51K13 Notification type: INITIAL NOTIFICATION Reference number: 157184/4/4 ____________________________________________ Transaction date: 2026-05-18 Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME) Instrument type: SHARE ISIN: FI4000480454 Nature of transaction:

    Bioretec Ltd's business review Q1 2026: Early Traction from Renewed Strategy

    Bioretec Ltd. | Company announcement | 15 May 2026 at 9:00 a.m. This announcement summarizes Bioretec Ltd's business review for January-March 2026. The complete business review is attached to this release as a PDF file and available on the company's website at https://investors.bioretec.com/en/reports_and_presentations. January–March 2026 in brief · Net sales amounted to EUR 1,220 thousand (1–3/2025: EUR 1,396 thousand) · Adjusted sales margin was 70.1% (56.7%) of net sales. From Q1/2026, the company will transition to reporting adjusted sales margin to be aligned with

    Bioretec clarifies its 2026–2028 financial target regarding the sales margin

    Bioretec Ltd  Company release 13 May 2026 at 14:00 p.m. EEST Bioretec clarifies its 2026–2028 financial target regarding the sales margin   To be aligned with industry reporting standards, Bioretec will transition to reporting an adjusted sales margin from Q1/2026 onwards, as compared to the previously reported sales margin. The adjusted sales margin describes the profitability of implant sales before commercialization-related expenses, such as sales commissions. This change improves the transparency of Bioretec's performance in its core business and ensures alignment with industry

    Bioretec Ltd's resolutions of the constitutive meeting of the Board of Directors

    Bioretec Ltd  Company release 8 May 2026 at 20:40 p.m. EEST Bioretec Ltd's resolutions of the constitutive meeting of the Board of Directors   At its constitutive meeting held after the Annual General Meeting, the Board of Directors of Bioretec Ltd elected Kustaa Poutiainen as the Chairperson of the Board and David Gill as the Deputy Chairperson. The members of the committees were elected as follows: Audit Committee: Päivi Malinen (Chairperson), Michael Piccirillo and David Gill. Remuneration Committee: Justin Barad (Chairperson), Antti Vasara and Michael Piccirillo.

    Bioretec Ltd's resolutions of the Annual General Meeting

    Bioretec Ltd  Company release 8 May 2026 at 14:45 p.m. EEST Bioretec Ltd's resolutions of the Annual General Meeting Bioretec Ltd's Annual General Meeting was held on Friday 8 May 2026 as a hybrid meeting in accordance with Chapter 5, Section 16, Subsection 2 of the Finnish Companies Act. The Annual General Meeting approved the financial statements for the financial year 1 January–31 December 2025 and resolved to discharge the members of the Board of Directors and the CEOs from liability for the financial period 1 January–31 December 2025. The Annual General Meeting resolved in

    Bioretec Ltd: Notification pursuant to Chapter 9, Section 10 of the Finnish Securities Markets Act (Sp-Rahastoyhtiö)

    Bioretec Ltd  Company release 29 April 2026 at 16:40 p.m. EEST   Bioretec Ltd: Notification pursuant to Chapter 9, Section 10 of the Finnish Securities Markets Act (Sp-Rahastoyhtiö) Bioretec Ltd ("Bioretec" or the "Company") has received on 29 April 2026 the following notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from Sp-Rahastoyhtiö Oy. According to the notification, the holding of Säästöpankki Pienyhtiöt, an investment fund of Sp-Rahastoyhtiö, in Bioretec's shares and votes has exceeded 5 per cent on 29 April 2026. The total number

    Bioretec Ltd – Manager’s transactions – Stephen Industries Inc Oy

    Bioretec Ltd – Manager’s transactions – Stephen Industries Inc Oy Bioretec Oy Company release 28 April 2026 at 16:55 p.m. EEST   Bioretec Oy - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Stephen Industries Inc Oy Position: Closely associated person (X) Legal person  (1):Person Discharging Managerial Responsibilities In Issuer Name: Kustaa Poutiainen Position: Member of the Board Issuer: Bioretec Oy LEI: 7437008736AG7HY51K13 Notification type: INITIAL NOTIFICATION Reference

    Bioretec Ltd: Notification pursuant to Chapter 9, Section 10 of the Finnish Securities Markets Act (Kustaa Poutiainen)

    Bioretec Ltd  Company release 28 April 2026 at 15:55 p.m. EEST   Bioretec Ltd: Notification pursuant to Chapter 9, Section 10 of the Finnish Securities Markets Act (Kustaa Poutiainen) Bioretec Ltd ("Bioretec" or the "Company") has received on 28 April 2026 the following notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from Kustaa Poutiainen. According to the notification, the holding of Stephen Industries Inc Oy, an entity controlled by Kustaa Poutiainen, in Bioretec's shares and votes has exceeded 30 per cent on 28 April 2026. The

    Bioretec Ltd adjusts the terms and conditions of its stock option programs due to the completed rights issue

    Bioretec Ltd  Company announcement  28 April 2026 at 13:40 p.m. EEST Bioretec Ltd adjusts the terms and conditions of its stock option programs due to the completed rights issue As previously announced, Bioretec Ltd ("Bioretec" or the "Company") has completed a rights issue (the "Offering"), in which a total of 1,286,801,534 new shares of the Company were subscribed for. The new shares subscribed for in the Offering have been registered with the trade register maintained by the Finnish Patent and Registration Office on 28 April 2026. Under the terms and conditions of the Company's

    New shares of Bioretec Ltd registered with the trade register

    Bioretec Ltd  Company announcement  28 April 2026 at 13:10 EEST New shares of Bioretec Ltd registered with the trade register NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. As previously announced, Bioretec Ltd ("Bioretec" or the "Company") has completed its rights issue (the "Offering")

    Bioretec Ltd - Manager's transactions - Paavola

    Bioretec Oy Company Release 27 April 2026 at 4:00 p.m. EEST Bioretec Oy - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Tuukka Paavola Position: Chief Financial Officer Issuer: Bioretec Oy LEI: 7437008736AG7HY51K13 Notification type: INITIAL NOTIFICATION Reference number: 153482/4/4 ____________________________________________ Transaction date: 2026-04-24 Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME) Instrument type: SHARE ISIN: FI4000480454 Nature of transaction:

    Final results of Bioretec Ltd's rights issue

    Bioretec Ltd   Company announcement   24 April 2026 at 6:45 p.m. EESTNOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. The final results of Bioretec Ltd's ("Bioretec" or the "Company") rights issue (the "Offering") show that a total of 1,286,801,534 new shares (the "New Shares") were subscribed

    Inside information: Preliminary result of Bioretec Ltd's rights issue

    Bioretec Ltd  Inside information 23 April 2026 at 4:00 p.m. EESTNOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Bioretec Ltd ("Bioretec" or the "Company") announced on 27 March 2026 that the Board of Directors of Bioretec has decided to offer Bioretec's shareholders up to 1,477,828,416 new

    NOTICE OF THE ANNUAL GENERAL MEETING OF BIORETEC LTD

    Bioretec Ltd    Notice to general meeting      20 April 2026 at 4:30 p.m. EESTThe shareholders of Bioretec Ltd are hereby invited to the Annual General Meeting to be held on 8 May 2026  at 11:00 a.m. (Finnish time) at Bioretec premises in the auditorium of Tampark, at the address Yrittäjänkulma 5, FI-33710 Tampere, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 10:30 a.m. (Finnish time) at the meeting venue.   The meeting will be held as a hybrid meeting in accordance with chapter 5, section 16, subsection

    Bioretec Ltd – Manager’s transactions – Stephen Industries Inc Oy

    Bioretec Oy Company release 15 April 2026 at 12:00 p.m. EEST   Bioretec Oy - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Stephen Industries Inc Oy Position: Closely associated person (X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer Name: Kustaa Poutiainen Position: Member of the Board Issuer: Bioretec Oy LEI: 7437008736AG7HY51K13 Notification type: INITIAL NOTIFICATION Reference number: 151618/4/4 ____________________________________________

    Bioretec Ltd publishes an exemption document relating to its rights issue

    Bioretec Ltd  Company release 2 April 2026 at 3:00 p.m. EEST Bioretec Ltd publishes an exemption document relating to its rights issue NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Bioretec Ltd ("Bioretec" or the "Company") announced on 27 March 2026 that it is commencing a rights

    Inside information: Bioretec Ltd's Board of Directors resolved on a rights issue of up to approximately EUR 14.8 million and publishes the terms and conditions of the rights issue

    Bioretec Ltd  Inside information 27 March 2026 at 12:50 p.m. EET Inside information: Bioretec Ltd's Board of Directors resolved on a rights issue of up to approximately EUR 14.8 million and publishes the terms and conditions of the rights issue NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe